2025年4月5日 周六
首页 > 按月查看>2020年第10月 >856-860
PDF 导出
高密度脂蛋白功能改变对心血管疾病和围手术期心血管保护的影响
作者:
作者单位:

(1.哈尔滨医科大学,黑龙江省哈尔滨市150081;2.中山大学附属第一医院心脏外科,广东省广州市 510080;3.血管疾病诊治技术国家地方联合工程实验室(广东) 国家卫健委辅助循环重点实验室(中山大学) 广东省血管疾病诊治工程技术研究中心 广东省脑功能与脑疾病重点实验室,广东省广州市 510080;4.中山大学附属第一医院高血压血管病科,广东省广州市 510080)

作者简介:

区乐淳,研究方向为临床医学,E-mail为lechunou@163.com。通信作者欧志君,博士,主任医师,研究方向为心血管疾病,E-mail为Zhijunou@163.com。

基金项目:

国家自然科学基金项目(81670392、81830013、81970363)；国家科技部国际合作专项(2015DFA31070)；广东省自然科学基金研究团队项目(2015A030312009)


Effects of high density lipoprotein function change on cardiovascular diseases and perioperative cardiovascular protection
Author:
  • OU Lechun 1

    OU Lechun

    Harbin Medical University, Harbin, Heilongjiang 150081, China
    在知网中查找
    在百度中查找
    在本站中查找
  • PENG Yueming 2,3

    PENG Yueming

    Division of Cardiac Surgery, Heart Center, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China;National-Guangdong Joint Engineering Laboratory for Diagnosis and Treatment of Vascular Diseases & NHC Key Laboratory of Assisted Circulation Sun Yat-sen University & Guangdong Provincial Engineering and Technology Center for Diagnosis and Treatment of Vascular Diseases & Guangdong Provincial Key Laboratory of Brain Function and Disease, Guangzhou, Guangdong 510080, China
    在知网中查找
    在百度中查找
    在本站中查找
  • OU Zhijun 3,4

    OU Zhijun

    National-Guangdong Joint Engineering Laboratory for Diagnosis and Treatment of Vascular Diseases & NHC Key Laboratory of Assisted Circulation Sun Yat-sen University & Guangdong Provincial Engineering and Technology Center for Diagnosis and Treatment of Vascular Diseases & Guangdong Provincial Key Laboratory of Brain Function and Disease, Guangzhou, Guangdong 510080, China;Division of Hypertension and Vascular Diseases, Heart Center, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China
    在知网中查找
    在百度中查找
    在本站中查找
Affiliation:

1.Harbin Medical University, Harbin, Heilongjiang 150081, China;2.Division of Cardiac Surgery, Heart Center, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China;3.National-Guangdong Joint Engineering Laboratory for Diagnosis and Treatment of Vascular Diseases & NHC Key Laboratory of Assisted Circulation (Sun Yat-sen University) & Guangdong Provincial Engineering and Technology Center for Diagnosis and Treatment of Vascular Diseases & Guangdong Provincial Key Laboratory of Brain Function and Disease, Guangzhou, Guangdong 510080, China;4. Division of Hypertension and Vascular Diseases, Heart Center, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China)

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献
    • |
  • 相似文献
    • |
  • 引证文献
    • |
    摘要:

    高密度脂蛋白(HDL)成分复杂,功能容易发生变异。正常HDL是一种保护性脂蛋白,有保护心血管的功能。但最近研究发现HDL成分和功能不但在冠心病、心脏瓣膜病变、动脉瘤、心功能不全等心血管疾病状态下发生改变,而且在心血管手术围手术期也发生改变。正常人的HDL趋炎指数很低,但心血管疾病状态下HDL趋炎指数变得很高,损伤血管内皮功能,影响心脏手术后血流动力学的稳定。载脂蛋白A-Ⅰ模拟肽、辛伐他汀等可部分改善HDL功能。如何改善HDL的功能,使其恢复保护心血管的作用,预防心血管疾病和增强围手术期心血管保护是将来的研究方向。

    Abstract:

    The composition of high density lipoprotein (HDL) is complex and its function is prone to change. Normal HDL is a protective lipoprotein, which can protect cardiovascular function. However, recent studies have found that HDL composition and function change not only in coronary heart disease, heart valve disease, aneurysm, heart failure, heart transplantation and other cardiovascular diseases, but also in the cardiovascular perioperative period. The HDL proinflammatory index in normal people is very low, but it becomes very high under the condition of cardiovascular disease, which impairs vascular endothelial function and affects the stability of hemodynamics after cardiac surgery. Apolipoprotein A-Ⅰ mimetic peptide and simvastatin can partially improve HDL function. Therefore, how to improve the function of HDL, and restore its protective cardiovascular effect to prevent cardiovascular diseases and enhance cardiovascular protection in perioperative period need to be studied in the future.

    参考文献
    [1] Furtado JD, Yamamoto R, Melchior JT, et al.Distinct proteomic signatures in 16 HDL (high-density lipoprotein) subspecies .Arterioscler Thromb Vasc Biol, 8,8:2827-2842.
    [2] Peterson SJ, Shapiro JI, Thompson E, et al.Oxidized HDL, adipokines, and endothelial dysfunction:a potential biomarker profile for cardiovascular risk in women with obesity .Obesity (Silver Spring), 9,7:87-93.
    [3] Ishikawa H, Yamada H, Taromaru N, et al.Stability of serum high-density lipoprotein-microRNAs for preanalytical conditions .Ann Clin Biochem, 7,4:134-142.
    [4] Ertek S.High-density lipoprotein (HDL) dysfunction and the future of HDL .Curr Vasc Pharmacol, 8,6:490-498.
    [5] Samadi S, Mehramiz M, Kelesidis T, et al.High-density lipoprotein lipid peroxidation as a molecular signature of the risk for developing cardiovascular disease:results from mashad cohort .J Cell Physiol, 2019.DOI:10.1002/jcp.28276.
    [6] Eisenberg S.High density lipoprotein metabolism .J Lipid Res, 4,5:1017-1058.
    [7] Li ZH, Lv YB, Zhong WF, et al.High-density lipoprotein cholesterol and all-cause and cause-specific mortality among the elderly.J Clin Endocrinol Metab, 9,4(8):3370-3378.
    [8] Hamer M, O'Donovan G, Stamatakis E.High-density lipoprotein cholesterol and mortality:too much of a good thing?.Arterioscler Thromb Vasc Biol, 8,8:669-672.
    [9] Bowe B, Xie Y, Xian H, et al.High density lipoprotein cholesterol and the risk of all-cause mortality among U.S.veterans.Clin J Am Soc Nephrol, 6,1:1784-1793.
    [10] Fanni G, Rosato R, Gentile L, et al.Is HDL cholesterol protective in patients with type 2 diabetes? A retrospective population-based cohort study.J Transl Med, 0,8:189.
    [11] Zanoni P, Khetarpal SA, Larach DB, et al.Rare variant in scavenger receptor bi raises HDL cholesterol and increases risk of coronary heart disease.Science, 6,1:1166-1171.
    [12] Voight BF, Peloso GM, Orho-Melander M, et al.Plasma HDL cholesterol and risk of myocardial infarction:a mendelian randomisation study.Lancet, 2,0:572-580.
    [13] Kastelein JJ, van Leuven SI, Burgess L, et al.Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.N Engl J Med, 7,6:1620-1630.
    [14] Nissen SE, Tardif JC, Nicholls SJ, et al.Effect of torcetrapib on the progression of coronary atherosclerosis.N Engl J Med, 7,6:1304-1316.
    [15] Schwartz GG, Olsson AG, Abt M, et al.Effects of dalcetrapib in patients with a recent acute coronary syndrome.N Engl J Med, 2,7:2089-2099.
    [16] Landray MJ, Haynes R, Hopewell JC, et al.Effects of extended-release niacin with laropiprant in high-risk patients.N Engl J Med, 4,1:203-212.
    [17] Bowman L, Hopewell JC, Chen F, et al.Effects of anacetrapib in patients with atherosclerotic vascular disease.N Engl J Med, 7,7:1217-1227.
    [18] van Capelleveen JC, Brewer HB, Kastelein JJ, et al.Novel therapies focused on the high-density lipoprotein particle.Circ Res, 4,4:193-204.
    [19] Chang FJ, Yuan HY, Hu XX, et al.High density lipoprotein from patients with valvular heart disease uncouples endothelial nitric oxide synthase.J Mol Cell Cardiol, 4,4:209-219.
    [20] Ansell BJ, Navab M, Hama S, et al.Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.Circulation, 3,8:2751-2756.
    [21] Souza FR, Dos Santos MR, Porello RA, et al.Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic androgenic steroid users.Atherosclerosis, 9,3:100-105.
    [22] Miki T, Miyoshi T, Kotani K, et al.Decrease in oxidized high-density lipoprotein is associated with slowed progression of coronary artery calcification:subanalysis of a prospective multicenter study.Atherosclerosis, 9,3:1-6.
    [23] Besler C, Heinrich K, Rohrer L, et al.Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.J Clin Invest, 1,1:2693-2708.
    [24] Adams V, Besler C, Fischer T, et al.Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.Circ Res, 3,3:1345-1355.
    [25] Gonzlez FEM, Ponce-Ruíz N, Rojas-García AE, et al.PON1 concentration and high-density lipoprotein characteristics as cardiovascular biomarkers.Arch Med Sci Atheroscler Dis, 9,4:e47-e54.
    [26] 欧志君, 常凤军, 胡晓侠, 等.高胆固醇血症患者的高密度脂蛋白损伤血管功能.中国动脉硬化杂志, 5,3(12):1192-1196.
    [27] 李华明, 欧志君, 李艳, 等.高密度脂蛋白功能改变可能是动脉粥样硬化形成的危险因素.中国动脉硬化杂志, 5,3:1189-1191.
    [28] Sviridov D, Chin-Dusting J, Nestel P, et al.Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients:evidence for impaired reverse cholesterol transport.Transplantation, 6,1(3):361-366.
    [29] Delbosc S, Diallo D, Dejouvencel T, et al.Impaired high-density lipoprotein anti-oxidant capacity in human abdominal aortic aneurysm.Cardiovasc Res, 3,0:307-315.
    [30] Burillo E, Jorge I, Martinez-Lopez D, et al.Quantitative HDL proteomics identifies peroxiredoxin-6 as a biomarker of human abdominal aortic aneurysm.Sci Rep, 6,6:38477.
    [31] Martinez-Lopez D, Camafeita E, Cedo L, et al.APOA1 oxidation is associated to dysfunctional high-density lipoproteins in human abdominal aortic aneurysm.EBioMedicine, 9,3:43-53.
    [32] Liu YY, Lin SJ, Chen YY, et al.High-density lipoprotein cholesterol as a predictor of poor survival in patients with nasopharyngeal carcinoma.Oncotarget, 6,7:42978-42987.
    [33] Luo F, Zeng KM, Zhang ZH, et al.Prognostic value of serum high-density lipoprotein cholesterol elevation in nonsmall cell lung cancer patients receiving radical surgery.Clin Transl Med, 2020.DOI:10.1002/ctm1002.1094.
    [34] Riwanto M, Rohrer L, Roschitzki B, et al.Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease:role of high-density lipoprotein-proteome remodeling.Circulation, 3,7:891-904.
    [35] Alwaili K, Bailey D, Awan Z, et al.The HDL proteome in acute coronary syndromes shifts to an inflammatory profile.Biochim Biophys Acta, 2,1:405-415.
    [36] Wang X, Liu X, Xie Z, et al.Small HDL subclass is associated with coronary plaque stability:an optical coherence tomography study in patients with coronary artery disease.J Clin Lipidol, 9,3:326-334.
    [37] Delbosc S, Rouer M, Alsac JM, et al.High-density lipoprotein therapy inhibits porphyromonas gingivalis-induced abdominal aortic aneurysm progression.Thromb Haemost, 6,5:789-799.
    [38] Huang Y, Wu Z, Riwanto M, et al.Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex.J Clin Invest, 3,3:3815-3828.
    [39] Shao B, Tang C, Sinha A, et al.Humans with atherosclerosis have impaired abca1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase.Circ Res, 4,4:1733-1742.
    [40] Hewing B, Parathath S, Barrett T, et al.Effects of native and myeloperoxidase-modified apolipoprotein a-Ⅰ on reverse cholesterol transport and atherosclerosis in mice.Arterioscler Thromb Vasc Biol, 4,4:779-789.
    [41] Huang Y, Didonato JA, Levison BS, et al.An abundant dysfunctional apolipoprotein A1 in human atheroma.Nat Med, 4,0:193-203.
    [42] Hacquebard M, Ducart A, Schmartz D, et al.Changes in plasma LDL and HDL composition in patients undergoing cardiac surgery.Lipids, 7,2:1143-1153.
    [43] Zewinger S, Drechsler C, Kleber ME, et al.Serum amyloid a:high-density lipoproteins interaction and cardiovascular risk.Eur Heart J, 5,6:3007-3016.
    [44] Vickers KC, Palmisano BT, Shoucri BM, et al.MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.Nat Cell Biol, 1,3:423-433.
    [45] Li HM, Mo ZW, Peng YM, et al.Angiogenic and antiangiogenic mechanisms of high density lipoprotein from healthy subjects and coronary artery diseases patients.Redox Biol, 0,6:101642.DOI:10.1016/j.redox.2020.101642.
    [46] Ou J, Wang J, Xu H, et al.Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-Ⅰ double-knockout mice on Western diet.Circ Res, 5,7:1190-1197.
    [47] Sharma S, Umar S, Potus F, et al.Apolipoprotein A-Ⅰ mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p.Circulation, 4,0:776-785.
    [48] 应如, 袁勇, 秦亚飞, 等.模拟肽L-4F对动脉粥样硬化小鼠的保护作用及机制.中国循环杂志, 3,8:379-383.
    [49] Ou J, Ou Z, Jones DW, et al.L-4f, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease.Circulation, 3,7:2337-2341.
    [50] Ou Z, Ou J, Ackerman AW, et al.L-4f, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells.Circulation, 3,7:1520-1524.
    [51] Mune M, Uto-Kondo H, Iteya I, et al.Vitamin e supplementation improves high-densitiy lipoprotein and endothelial functions in end-stage kidney disease patients undergoing hemodialysis.Clin Nephrol, 8,0:212-221.
    相似文献
    引证文献
引用本文

区乐淳,彭月明,欧志君.高密度脂蛋白功能改变对心血管疾病和围手术期心血管保护的影响[J].中国动脉硬化杂志,2020,28(10):856~860.

复制
分享
文章指标
  • 点击次数:723
  • 下载次数: 664
历史
  • 收稿日期:2020-04-07
  • 最后修改日期:2020-08-25
  • 在线发布日期: 2020-10-20

您是本站第 4760640 访问者

邮编：421001 传真：0734-8160523

电话：0734-8160765 E-mail：dmzzbjb@163.net

中国动脉硬化杂志 ® 2025 网站版权所有